TTNP Archives - Page 2 of 4

Markets

Maxim ups Titan Pharma to buy from hold; PT $11

Maxim Group upgraded Titan Pharmaceuticals (NASDAQ:TTNP) to “buy” from “hold” with a new price target of $11, citing multiple strategy, management, cap-structure and financing changes at Titan, which should position the...

February 18, 2021

Developments

Titan Pharma posts positive early study results for JT-09 ProNeura program

Titan Pharmaceuticals (NASDAQ:TTNP) announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and specificity for the human kappa-opioid receptor (KOR). JT-09 is being developed...

February 1, 2021

Developments

Titan Pharma completes debt settlement with Molteni and Horizon; acquisition of JT-09

Titan Pharmaceuticals (NASDAQ:TTNP) settled all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio and Horizon Credit, as well as the acquisition of JT Pharmaceuticals’ JT-09. Completion...

November 2, 2020

Developments

Titan Pharma to acquire JT-09 to develop ProNeura-based chronic pruritus treatment

Titan Pharmaceuticals (NASDAQ:TTNP) inked an agreement to acquire JT Pharmaceuticals’ kappa opioid agonist peptide, JT-09, for use in combination with Titan’s ProNeura long-term, continuous drug delivery technology, for...

October 28, 2020

Developments

Titan Pharma in debt settlement pact with Molteni and Horizon

Titan Pharmaceuticals (NASDAQ:TTNP) inked an agreement to settle all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio and Horizon Credit. The debt was secured with a lien on all assets...

October 26, 2020

Developments

Titan Pharma to focus on ProNeura-based product development

Titan Pharmaceuticals (NASDAQ:TTNP) reported that it will discontinue U.S. Probuphine sales and wind down commercialization activities as it restructures to focus on ProNeura-based product development. “Marketing of...

October 15, 2020

Developments

Titan Pharma Probuphine commercialization partner inks European distribution agreement

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine commercialization partner, Molteni, signed an exclusive European distribution agreement with Accord Healthcare Europe for the commercialization of Sixmo, the brand name...

September 15, 2020

Developments

Titan Pharma and Indegene provide details of new Probuphine co-promotion partnership

Titan Pharmaceuticals’ (NASDAQ:TTNP) CEO, Sunil Bhonsle, and Indegene VP of co-commercialization, Jamie Peck, provided additional information on their recently established Probuphine co-promotion partnership. In an...

July 29, 2020

Developments

Titan Pharma and Indegene sign Probuphine co-promotion partnership

Titan Pharmaceuticals (NASDAQ:TTNP) signed a co-promotion partnership with Indegene to establish multichannel digital marketing programs across the U.S. and engage health care providers (HCPs) who are eligible to...

June 24, 2020

Developments

Titan Pharma’s Probuphine added to Federal Supply Schedule

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant, a novel six-month maintenance treatment for opioid use disorder (OUD), will be included on the Federal Supply Schedule (FSS) beginning on January 15, 2020. The...

January 13, 2020

Tag - TTNP

Maxim ups Titan Pharma to buy from hold; PT $11

Titan Pharma posts positive early study results for JT-09 ProNeura program

Titan Pharma completes debt settlement with Molteni and Horizon; acquisition of JT-09

Titan Pharma to acquire JT-09 to develop ProNeura-based chronic pruritus treatment

Titan Pharma in debt settlement pact with Molteni and Horizon

Titan Pharma to focus on ProNeura-based product development

Titan Pharma Probuphine commercialization partner inks European distribution agreement

Titan Pharma and Indegene provide details of new Probuphine co-promotion partnership

Titan Pharma and Indegene sign Probuphine co-promotion partnership

Titan Pharma’s Probuphine added to Federal Supply Schedule

General

More